Becton, Dickinson and Company Common Stock (BDX)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Jul 10, 2026Investment Snapshot
- Trading 91% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 3.9% — below-average profitability
- Revenue growing at 8% annually
Becton, Dickinson and Company Common Stock (BDX) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $43.6 billion . Key value metrics: P/E ratio 45.7, P/B ratio 1.80, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Becton, Dickinson and Company Common Stock — Fundamental Analysis Summary
Becton, Dickinson and Company Common Stock (BDX) is currently trading 91% above its Graham Number of $82.56, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 45.7x.
On financial health, BDX shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and modest return on equity of 3.9% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.72.
StockPik's composite Value Score for BDX is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BDX reports a solid gross margin of 45.6% (sector average: 39.4%) and a modest operating margin of 10.0%.
BDX shows revenue growing at 8% year-over-year, with earnings declining at 2%.
BDX pays a modest dividend yield of 2.6%.